<DOC>
	<DOCNO>NCT00860093</DOCNO>
	<brief_summary>The purpose study evaluate efficacy MP-5971 facilitate stone passage Shock Wave Lithotripsy treatment .</brief_summary>
	<brief_title>Efficacy Safety Using MPC-5971 Subjects Undergoing Shock Wave Lithotripsy</brief_title>
	<detailed_description>Shock Wave Lithotripsy ( SWL ) widely utilize first line therapy patient renal calculus . SWL associate limited morbidity , however , complication relate stone fragment passage treatment occur , serious ureter obstruction . In addition , growth agglomeration residual fragment SWL treatment , approximately 40 % patient , lead another stone episode within 12 month . Adjunct therapy MPC-5971 reduce risk complication residual stone fragment facilitating passage , prevent blockage inhibit growth enlargement residual fragment . This base MPC-5971 's ability increase urinary inhibitor growth agglomeration stone fragment reduce urinary saturation calcium oxalate uric acid . The objective see decrease fragment complication significant increase stone free rate 3 month follow SWL treatment combination MPC-5971 .</detailed_description>
	<mesh_term>Nephrolithiasis</mesh_term>
	<mesh_term>Kidney Calculi</mesh_term>
	<criteria>Inclusion criterion : Male female subject age &gt; equal 18 &lt; equal 70 . Subject undergone computerize tomography ( CT ) scan within 30 day screen visit . Subject diagnose single unilateral renal calculus ( target treatment stone ) . Target treatment stone , presumed calcium composition and/or uric acid composition . Target treatment stone &gt; equal 5 &lt; equal 15 mm diameter . Contra lateral kidney may hold clinically inconsequential size calculus require concurrent SWL treatment . Both kidney anatomically normal . An appropriate candidate SWL , determine treat physician . Female subject negative pregnancy test , hysterectomy , tubal ligation nonchild bear potential ( postmenopausal ) . Female subject child bear potential negative pregnancy test take appropriate birth control duration study . Urine pyuria negative nitrite negative dipstick and/or negative upon microscopic evaluation . Subject must voluntarily consent participate study provide his/her write informed consent prior start studyspecific procedure . Current past history cystine stone infection stone . Renal insufficiency , define serum creatinine value outside normal reference range . Currently hyperkalemia within past six month , define serum potassium outside normal reference range . Currently hypermagnesemia within past six month , define serum magnesium outside normal reference range . Active urinary tract infection . Renal calculus anatomically abnormal kidney ; horseshoe shape , ureteropelvic junction obstruction calyceal diverticulum . Altered urinary tract anatomy transplant kidney , urinary reconstruction congenital anomaly . Blood coagulopathies take anticoagulant ( warfarin , coumarin , heparin ) . Taking salicylate ( aspirin ) , include low dose aspirin cardioprophylaxis NSAID ( OTC ) may increase bleeding time , within past 7 day . History complication previous SWL ; pyelonephritis , perinephric hematoma . Unsuccessful SWL treatment previous stone within past six month . Currently previously ulcers esophagus , stomach and/or small intestine . Chronic diarrhea history diarrhea . Bowel disease Crohn 's disease , Celiac disease , fat malabsorption Sprue . Undergone bariatric surgery procedure . Obese , define BMI &gt; 30 . Uncontrolled hypertension define subject take medication specific hypertension subject medication systolic blood pressure 140 diastolic 90 . Adrenal insufficiency ( i.e. , Addison 's disease ) , adrenal tumor , and/or subject adrenal hormone replacement therapy . Taking potassiumsparing diuretic ( triamterene , amiloride , spironolactone , Midamor® , Aldactone® , Dyrenium® , Eplerenone® ) . Taking potassium supplement ( Rx OTC ) within past 15 day . Taking magnesium supplement ( Rx OTC ) within past 15 day . Taken potassium citrate supplement ( Rx OTC ) within past 30 day . Subject take anticholinergic medication entry ( dicyclomine , atropine , scopolamine , oxybutynin , tolerodine , Cogentin® , Sinemet® , Robinal® , Kenadrin® , Artane® , Enablex® , Detrol® , Vesicare® , Sanctura® , Ditropan® , Oxytrol® , Bentyl® , Byclomine® , Dibent® , DiSpaz® , Dilomine® ) . ( Subjects may prescribe anticholinergic standard care use stent post entry . ) Subject take gastrointestinal enzyme replacement therapy proton pump inhibitor within past 30 day ( Ultrase® , Creon® , Viokase® , Pancrease® MT , pancrelipase agent , Aciphex® , Nexium® , Prevacid® , Protonix® , Zegerid® Prilosec OTC® , Kapidex® , rabeprazole , esomeprazole , lansoprazole , pantoprazole , omeprazole , dexlansoprazole ) . Women pregnant lactating . Subjects know hypersensitivity potassium , magnesium , citrate excipients drug formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Kidney Calculi</keyword>
	<keyword>Urolithiasis</keyword>
	<keyword>Lithotripsy</keyword>
	<keyword>potassium compound</keyword>
	<keyword>magnesium compound</keyword>
</DOC>